Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share. This represents a substantial upside from the current share price
Respected Wall Street analyst Dr Raghuram Selvaraju has published new research on Cynata: “Raising price target—anticipating further milestones near-term. We believe that Cynata is entering a catalyst-rich period, with the possible option exercise near-term in its arrangement with Fujifilm...”
With 11 reasons to consider Cynata Therapeutics and an expected total share holder return of 331%, NDF sees a price target of $2.00 per share based on a probability-weighted valuation model.
Based on NPV based valuation, we believe that Cynata Therapeutics is substantially undervalued at the current share price of AUD 0.57. Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share
More Information: http://www.leeuwenhoeck.com
Cynata Therapeutics Limited
Market Cap (MM): A$37.8
A unique production method. CYP’s CymerusTM technology is the only likely viable production method for generating medicinal mesenchymal stem cells (MSC) for large scale clinical applications. We are not aware of any competing technology under development that is a scalable method of growing MSCs which don’t lose potency as successive generations of cells are produced and do not rely on multiple cell donors. Trial data and third party validation of CYP’s MSCs and the opportunity for them continues to build. Fujifilm has taken an 8.9% equity position in CYP and optioned the global rights for use in graft-versus-host disease (GvHD). apceth Biopharma GmbH has conducted due diligence on the production method and found the characteristics of the cells produced using Cymerus were highly satisfactory. The UK regulator has approved a first trial in humans validating safety and manufacturing procedure. CYPs pre-clinical trials have shown the MSCs produced performed very favourably and independent studies have provided further verification.